Wagstaff, J., Woods, B. S., Sideris, E., Sydes, M. R., Gannon, M. R., Parmar, M. K., . . . Sculpher, M. J. (2018). Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. European Urology Oncology, 1(6), pp. 449-458. doi:10.1016/j.euo.2018.06.004

Wagstaff, John, et al. "Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness." European Urology Oncology 1, no. 6 (2018): 449-458.

Wagstaff, John, et al. "Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness." European Urology Oncology 1.6 (2018): 449-458.